Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

20.30USD
2 Dec 2016
Change (% chg)

$0.05 (+0.25%)
Prev Close
$20.25
Open
$20.20
Day's High
$20.50
Day's Low
$19.85
Volume
434,733
Avg. Vol
613,980
52-wk High
$43.63
52-wk Low
$16.40

ACOR.O

Chart for ACOR.O

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $940.73
Shares Outstanding(Mil.): 46.11
Dividend: --
Yield (%): --

Financials

  ACOR.O Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.49 -- --
ROI: -2.11 -1.09 14.95
ROE: -3.60 -2.39 16.29

BRIEF-Acorda to discontinue development of Dalfampridine for treatment of post-stroke walking difficulties

* Milestone clinical study did not show sufficient efficacy to support further development of dalfampridine to improve pswd

Nov 21 2016

BRIEF-Acorda Therapeutics Q3 non-GAAP loss per share $0.04

* Acorda provides financial and pipeline update for third quarter 2016

Oct 27 2016

BRIEF-Acorda Therapeutics presents data from clinical and preclinical trials of CVT-301

* Acorda Therapeutics Inc-presents data from clinical and preclinical trials of CVT-301 for treatment of OFF periods in Parkinson's disease

Oct 13 2016

BRIEF-Arbitral Tribunal confirms Acorda's redemption right regarding Biotie shares

* Arbitral Tribunal confirmed Acorda's redemption right regarding Biotie shares

Sep 26 2016

BRIEF-Acorda presents phase 1 data on Migraine drug at 58th annual meeting of American Headache Society

* There were no serious adverse events, dose limiting toxicities, study discontinuations due to adverse events reported for cvt-427

Jun 09 2016

Earnings vs. Estimates